Kineta Inc

Kineta Inc

KA - Insider Information

Get informed when a big investor buys or sells

+ Follow
Market Cap$7.05M
Close$

Compare to Similar Companies

P/E RatioDividendsReturn on EquityPrice-to-SalesDebt-to-Equity
Kineta IncKineta Inc-0.4-58%--0.4

Insider Trades

Loading insider trades…

Congress Trades

Loading congress trades…

Share Statistics

Market cap$7.05 Million
Enterprise Value$12.26 Million
Earnings per Share$-1.42
Beta0.57
Outstanding Shares12,902,000

Return

Return on Equity58.35%ROE
Return on Assets-914.25%
Return on Invested Capital64.34%

Valuation & Multiples

P/E Ratio-0.4P/E Ratio
PEG0.48PEG
Price to Sales-Price to Sales
Price to Book Ratio-0.29Price to Book Ratio
Enterprise Value to Revenue2.83
Enterprise Value to EBIT-1.44
Enterprise Value to Net Income-2
Total Debt to Enterprise0.45
Debt to Equity-0.42Debt to Equity

Revenue Sources

No data

Institutional Sentiment (Put/Call)

No data available for the latest quarter.

Institutional Ownership

No data available for the latest quarter.

About Kineta Inc

45 employees
CEO: Meenu Chhabra

Yumanity Therapeutics is a clinical-stage biopharmaceutical company dedicated to accelerating the revolution in the treatment of neurodegenerative diseases through its scientific foundation and drug discovery platform. The Company's most...

Kineta Insider Information FAQ

In the latest 13F quarter on Stockcircle, 2 top investors reduced or sold among tracked top investors. Changes are based on reported share counts in their quarterly filings, not day-to-day trading.

Form 4 insider trades are added as new filings are imported. Top investor 13F holdings refresh after each quarterly filing cycle. Politician trade disclosures are added when new reports are published on Stockcircle.